Influence of methyl-b-cyclodextrin on the relase kinetics of inulin encapsulated in bioadhesive liposomes

Peer reviewe

Contribution of cyclodextrins in the developement of different pharmaceutical formulations of a nex matrix metalloproteinase inhibitor

Ro 28-2653 is a new synthetic inhibitor of matrix metalloproteinases. The ability of these enzymes to degrade various components of the extracellular matrix seems to play a major role in tumors progression and is potentially effective against bronchial remodeling in asthma and BPCO. Ro 28-2653 is very poorly soluble in water. This low solubility estimated at about 0.56 lg/ml in water at 25 C gives rise to difficulties in pharmaceutical formulation of oral, injectable or nebulizable solutions. The purpose of our study is to prepare and to characterize inclusion complexes between Ro 28-2653 and cyclodextrins and to investigate the biopharmaceutical repercussion of the inclusion of the active substance.The complex formation was investigated by phase solubility studies. 1H-NMR spectroscopy and molecular modeling studies were carried out to elucidate the structure of the inclusion complex between Ro 28-2653 and cyclodextrin. Oral, intravenous and nebulizable solutions of Ro 28-2653 were developed with cyclodextrin. The in vivo studies were performed on healthy sheep for the pharmacokinetic evaluation of the oral and intravenous formulations while the nebulization of the complex solution was studied by using an asthma model in mouse

Double Encapsulation in liposomes for pulmonary administration produced by an innovative supercritical process

peer reviewe

Dévelopement de liposomes optimisés pour une administration transtympanique à libération prolongée

Development of a prolonged-release form based on dexamethasone for the local treatment of neuro-sensorial hearing los

Amphiphilic poly(N-vinylpyrrolidone)-based lipoplex modifiers for drug delivery applications

The abstract is provided in supported informatio